D

Dyne Therapeutics

Develops muscle-disease therapies using FORCE platform

Director, Revenue Accounting

Financial AccountingConfirmed live in the last 24 hours
Full-timeWaltham, MA, USA$200k - $230k

About the Job

Requirements

  • A bachelor's degree in Accounting, Finance, or a related field is required, and a Certified Public Accountant (CPA) credential is required.
  • At least 10 years of progressive accounting experience, including significant experience in biotech or pharmaceutical revenue accounting.
  • Hands-on experience with gross-to-net accounting, including rebates, chargebacks, distribution fees, and copay programs, in a specialty or branded pharmaceutical setting.
  • Strong technical knowledge of ASC 606 and its application to pharmaceutical product sales.
  • Experience designing and operating 404B SOX-compliant controls.
  • Experience working with distributors, specialty pharmacies, and/or group purchasing organizations and interpreting channel data.
  • Experience with rebate or contract management systems and enterprise resource planning systems, such as NetSuite.
  • Experience in a company scaling from a single-product launch to a multi-product portfolio.

Responsibilities

  • Own end-to-end revenue recognition for product sales in accordance with ASC 606, including contract review, performance obligation analysis, and variable consideration estimates.
  • Lead the monthly and quarterly revenue close process, including journal entries, account reconciliations, and flux analysis.
  • Implement and maintain accounting policies and technical memos supporting revenue recognition positions.
  • Implement, maintain, and refine gross-to-net estimation models covering rebates, chargebacks, distribution fees, prompt-pay discounts, returns, and copay or patient assistance programs.
  • Partner with Market Access, Trade, and Commercial teams to ensure gross-to-net assumptions reflect current contracts and market dynamics.
  • Monitor actual-to-estimate variances and true up accruals as new data becomes available.
  • Implement and maintain SOX-compliant internal controls over the revenue and gross-to-net accrual process.
  • Serve as the primary point of contact for external auditors on revenue-related matters, manage audit requests, and support technical accounting positions.
  • Ensure compliance with relevant SEC reporting requirements for 10-Q and 10-K revenue disclosures.
  • Partner with FP&A to support revenue forecasting, budgeting, and board and investor reporting.
  • Collaborate with Commercial Operations and Supply Chain on distributor and specialty pharmacy inventory data, including channel inventory and sell-through, used in revenue and gross-to-net calculations.
  • Present revenue and gross-to-net results to senior leadership, including trend analysis and risk commentary.
  • Lead evaluation and implementation of systems and tools to automate revenue and gross-to-net accounting as sales volume grows, such as contract management, rebate management software, and ERP revenue modules.
  • Build and document scalable processes as the company transitions from pre-commercial to multi-product commercial operations.
  • Manage external vendors supporting the end-to-end revenue cycle.

Desired Qualifications

  • Big Four public accounting background and industry experience are strongly preferred.

About the Company

Dyne Therapeutics

Develops muscle-disease therapies using FORCE platform

Dyne Therapeutics develops therapies for serious muscle diseases using its FORCE™ platform, which helps deliver oligonucleotide medicines to muscle tissue. Through a portfolio of experimental therapies, the company advances them in clinical trials (ACHIEVE and DELIVER) with the aim of treating rare muscle diseases. The product works by enhancing targeted delivery of oligonucleotides to muscle, enabling existing genetic medicines to reach affected tissues more effectively. Dyne differentiates itself by its proprietary FORCE™ technology and its focus on rare muscle diseases, positioning itself for growth as trials progress toward potential commercialization. The company’s goal is to bring effective treatments to patients and families affected by serious muscle diseases, expanding options as its therapies advance through development and, potentially, regulatory approval.

Company size
201-500
Company stage
IPO
Headquarters
Waltham, MA
Founded
2017

Recently Posted Jobs

Explore more opportunities at Dyne Therapeutics

See more jobs